Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16068-

  Fuchs, Sebastian P ^a,b   Desrosiers, Ronald C ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; ADENO ASSOCIATED VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; HAPLORHINI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; PRIORITY JOURNAL; RECOMBINANT ADENO ASSOCIATED VIRUS; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; VIRUS NEUTRALIZATION;

EID: 85015257690     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.68     Document Type: Review

References (387)

1. 1 Gottlieb, MS, Schroff, R, Schanker, HM, Weisman, JD, Fan, PT, Wolf, RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305 (1981), 1425–1431.
2. 2 Barré-Sinoussi, F, Chermann, JC, Rey, F, Nugeyre, MT, Chamaret, S, Gruest, J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983), 868–871.
3. 3 UNAIDS (2000). REPORT on the global HIV/AIDS epidemic. http://data.unaids.org/pub/Report/2000/2000_gr_en.pdf.
4. 4 UNAIDS (2013). Global report: UNAIDS report on the global AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf.
5. 5 Barré-Sinoussi, F, Ross, AL, Delfraissy, JF, Past, present and future: 30 years of HIV research. Nat Rev Microbiol 11 (2013), 877–883.
6. 6 Esparza, J, A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31 (2013), 3502–3518.
7. 7 Barry, SM, Mena Lora, AJ, Novak, RM, Trial, error, and breakthrough: a review of HIV vaccine development. J AIDS Clin Res, 5, 2014, 359.
8. 8 Girard, MP, Osmanov, S, Assossou, OM, Kieny, MP, Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 29 (2011), 6191–6218.
9. 9 Hütter, G, Nowak, D, Mossner, M, Ganepola, S, Müssig, A, Allers, K, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360 (2009), 692–698.
10. 10 Allers, K, Hütter, G, Hofmann, J, Loddenkemper, C, Rieger, K, Thiel, E, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117 (2011), 2791–2799.
11. 11 Yukl, SA, Boritz, E, Busch, M, Bentsen, C, Chun, TW, Douek, D, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog, 9, 2013, e1003347.
12. 12 Siliciano, JD, Siliciano, RF, Recent developments in the effort to cure HIV infection: going beyond N = 1. J Clin Invest 126 (2016), 409–414.
13. 13 Günthard, HF, Aberg, JA, Eron, JJ, Hoy, JF, Telenti, A, Benson, CA, et al., International Antiviral Society-USA Panel, Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312 (2014), 410–425.
14. 14 Nakagawa, F, May, M, Phillips, A, Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 26 (2013), 17–25.
15. 15 Siliciano, JD, Kajdas, J, Finzi, D, Quinn, TC, Chadwick, K, Margolick, JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9 (2003), 727–728.
16. 16 Strain, MC, Gunthard, HF, Havlir, DV, Ignacio, CC, Smith, DM, Leigh-Brown, AJ, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proceed Natl Acad Sci USA 100 (2003), 4819–4824.
17. 17 Finzi, D, Hermankova, M, Pierson, T, Carruth, LM, Buck, C, Chaisson, RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (1997), 1295–1300.
18. 18 Wong, JK, Hezareh, M, Günthard, HF, Havlir, DV, Ignacio, CC, Spina, CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278 (1997), 1291–1295.
19. 19 Chun, TW, Stuyver, L, Mizell, SB, Ehler, LA, Mican, JA, Baseler, M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Nati Acad Sci USA 94 (1997), 13193–13197.
20. 20 Finzi, D, Blankson, J, Siliciano, JD, Margolick, JB, Chadwick, K, Pierson, T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 (1999), 512–517.
21. 21 UNAIDS (2015), AIDS by the numbers. http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf.
22. 22 Desrosiers, RC, Prospects for an AIDS vaccine. Nat Med 10 (2004), 221–223.
23. 23 Desrosiers, RC, Strategies used by human immunodeficiency virus that allow persistent viral replication. Nat Med 5 (1999), 723–725.
24. 24 Lifson, JD, Haigwood, NL, Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Cold Spring Harb Perspect Med, 2, 2012, a007310.
25. 25 Flynn, NM, Forthal, DN, Harro, CD, Judson, FN, Mayer, KH, Para, MF, rgp120 HIV Vaccine Study Group, Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 (2005), 654–665.
26. 26 Jones, NG, DeCamp, A, Gilbert, P, Peterson, ML, Gurwith, M, Cao, H, AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27 (2009), 1136–1140.
27. 27 Gilbert, PB, Peterson, ML, Follmann, D, Hudgens, MG, Francis, DP, Gurwith, M, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191 (2005), 666–677.
28. 28 Gilbert, PB, Ackers, ML, Berman, PW, Francis, DP, Popovic, V, Hu, DJ, et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 192 (2005), 974–983.
29. 29 Pitisuttithum, P, Gilbert, P, Gurwith, M, Heyward, W, Martin, M, van Griensven, F, et al., Bangkok Vaccine Evaluation Group, Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194 (2006), 1661–1671.
30. 30 Buchbinder, SP, Mehrotra, DV, Duerr, A, Fitzgerald, DW, Mogg, R, Li, D, et al., Step Study Protocol Team, Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 (2008), 1881–1893.
31. 31 McElrath, MJ, De Rosa, SC, Moodie, Z, Dubey, S, Kierstead, L, Janes, H, et al., Step Study Protocol Team, HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 (2008), 1894–1905.
32. 32 Duerr, A, Huang, Y, Buchbinder, S, Coombs, RW, Sanchez, J, del Rio, C, et al., Step/HVTN 504 Study Team, Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206 (2012), 258–266.
33. 33 Koblin, BA, Mayer, KH, Noonan, E, Wang, CY, Marmor, M, Sanchez, J, et al. Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study. J Acquir Immune Defic Syndr 60 (2012), 405–413.
34. 34 Cheng, C, Wang, L, Gall, JG, Nason, M, Schwartz, RM, McElrath, MJ, et al. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PloS one, 7, 2012, e33969.
35. 35 Gray, GE, Allen, M, Moodie, Z, Churchyard, G, Bekker, LG, Nchabeleng, M, et al., HVTN 503/Phambili study team, Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11 (2011), 507–515.
36. 36 Gray, GE, Moodie, Z, Metch, B, Gilbert, PB, Bekker, LG, Churchyard, G, et al., HVTN 503/Phambili study team, Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect Dis 14 (2014), 388–396.
37. 37 Hammer, SM, Sobieszczyk, ME, Janes, H, Karuna, ST, Mulligan, MJ, Grove, D, et al., HVTN 505 Study Team, Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369 (2013), 2083–2092.
38. 38 Rerks-Ngarm, S, Pitisuttithum, P, Nitayaphan, S, Kaewkungwal, J, Chiu, J, Paris, R, et al., MOPH-TAVEG Investigators, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 (2009), 2209–2220.
39. 39 Gilbert, PB, Berger, JO, Stablein, D, Becker, S, Essex, M, Hammer, SM, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 203 (2011), 969–975.
40. 40 Haynes, BF, Gilbert, PB, McElrath, MJ, Zolla-Pazner, S, Tomaras, GD, Alam, SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366 (2012), 1275–1286.
41. 41 Montefiori, DC, Karnasuta, C, Huang, Y, Ahmed, H, Gilbert, P, de Souza, MS, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206 (2012), 431–441.
42. 42 Rolland, M, Edlefsen, PT, Larsen, BB, Tovanabutra, S, Sanders-Buell, E, Hertz, T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490 (2012), 417–420.
43. 43 Karasavvas, N, Billings, E, Rao, M, Williams, C, Zolla-Pazner, S, Bailer, RT, et al., MOPH TAVEG Collaboration, The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 28 (2012), 1444–1457.
44. 44 de Souza, MS, Ratto-Kim, S, Chuenarom, W, Schuetz, A, Chantakulkij, S, Nuntapinit, B, et al., Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators, The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188 (2012), 5166–5176.
45. 45 Liu, P, Yates, NL, Shen, X, Bonsignori, M, Moody, MA, Liao, HX, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol 87 (2013), 7828–7836.
46. 46 Zolla-Pazner, S, deCamp, AC, Cardozo, T, Karasavvas, N, Gottardo, R, Williams, C, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One, 8, 2013, e53629.
47. 47 Pollara, J, Bonsignori, M, Moody, MA, Liu, P, Alam, SM, Hwang, KK, et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88 (2014), 7715–7726.
48. 48 Johnson, PR, Schnepp, BC, Zhang, J, Connell, MJ, Greene, SM, Yuste, E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15 (2009), 901–906.
49. 49 Fuchs, SP, Martinez-Navio, JM, Piatak, M Jr, Lifson, JD, Gao, G, Desrosiers, RC, AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog, 11, 2015, e1005090.
50. 50 Gardner, MR, Kattenhorn, LM, Kondur, HR, von Schaewen, M, Dorfman, T, Chiang, JJ, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519 (2015), 87–91.
51. 51 Saunders, KO, Wang, L, Joyce, MG, Yang, ZY, Balazs, AB, Cheng, C, et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal Simian-human immunodeficiency virus infection. J Virol 89 (2015), 8334–8345.
52. 52 Balazs, AB, Chen, J, Hong, CM, Rao, DS, Yang, L, Baltimore, D, Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481 (2012), 81–84.
53. 53 Klein, F, Halper-Stromberg, A, Horwitz, JA, Gruell, H, Scheid, JF, Bournazos, S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492 (2012), 118–122.
54. 54 Horwitz, JA, Halper-Stromberg, A, Mouquet, H, Gitlin, AD, Tretiakova, A, Eisenreich, TR, et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Nati Acad Sci USA 110 (2013), 16538–16543.
55. 55 Halper-Stromberg, A, Lu, CL, Klein, F, Horwitz, JA, Bournazos, S, Nogueira, L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158 (2014), 989–999.
56. 56 Hessell, AJ, Jaworski, JP, Epson, E, Matsuda, K, Pandey, S, Kahl, C, et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med 22 (2016), 362–368.
57. 57 Barouch, DH, Whitney, JB, Moldt, B, Klein, F, Oliveira, TY, Liu, J, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
58. 58 Shingai, M, Nishimura, Y, Klein, F, Mouquet, H, Donau, OK, Plishka, R, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
59. 59 Lynch, RM, Boritz, E, Coates, EE, DeZure, A, Madden, P, Costner, P, et al., VRC 601 Study Team, Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med, 7, 2015, 319ra206.
60. 60 Caskey, M, Klein, F, Lorenzi, JC, Seaman, MS, West, AP Jr, Buckley, N, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
61. 61 Plotkin, S, History of vaccination. Proceed Natl Acad Sci USA 111 (2014), 12283–12287.
62. 62 Plotkin, SA, Plotkin, SL, The development of vaccines: how the past led to the future. Nat Rev Microbiol 9 (2011), 889–893.
63. 63 Turner, BG, Summers, MF, Structural biology of HIV. J Mol Biol 285 (1999), 1–32.
64. 64 Sierra, S, Kupfer, B, Kaiser, R, Basics of the virology of HIV-1 and its replication. J Clin Virol 34 (2005), 233–244.
65. 65 Smyth, RP, Davenport, MP, Mak, J, The origin of genetic diversity in HIV-1. Virus Res 169 (2012), 415–429.
66. 66 Hemelaar, J, The origin and diversity of the HIV-1 pandemic. Trends Mol Med 18 (2012), 182–192.
67. 67 Maartens, G, Celum, C, Lewin, SR, HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384 (2014), 258–271.
68. 68 McMichael, AJ, Borrow, P, Tomaras, GD, Goonetilleke, N, Haynes, BF, The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10 (2010), 11–23.
69. 69 Moir, S, Chun, TW, Fauci, AS, Pathogenic mechanisms of HIV disease. Annu Rev Pathol 6 (2011), 223–248.
70. 70 Sharp, PM, Hahn, BH, Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med, 1, 2011, a006841.
71. 71 Ho, DD, Neumann, AU, Perelson, AS, Chen, W, Leonard, JM, Markowitz, M, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995), 123–126.
72. 72 Burton, DR, Antibodies, viruses and vaccines. Nat Rev Immunol 2 (2002), 706–713.
73. 73 Douek, DC, Brenchley, JM, Betts, MR, Ambrozak, DR, Hill, BJ, Okamoto, Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 (2002), 95–98.
74. 74 Goulder, PJ, Watkins, DI, Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 8 (2008), 619–630.
75. 75 McMichael, A, Dorrell, L, The immune response to HIV. Medicine 37 (2009), 321–325.
76. 76 Picker, LJ, Hansen, SG, Lifson, JD, New paradigms for HIV/AIDS vaccine development. Annu Rev Med 63 (2012), 95–111.
77. 77 Migueles, SA, Connors, M, Success and failure of the cellular immune response against HIV-1. Nat Immunol 16 (2015), 563–570.
78. 78 Burton, DR, Mascola, JR, Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 16 (2015), 571–576.
79. 79 Zagury, D, Léonard, R, Fouchard, M, Réveil, B, Bernard, J, Ittelé, D, et al. Immunization against AIDS in humans. Nature 326 (1987), 249–250.
80. 80 IAVI (2016), IAVI Report - Clinical Trials Database. http://www.iavi.org/trials-database/.
81. 81 Lema, D, Garcia, A, De Sanctis, JB, HIV vaccines: a brief overview. Scand J Immunol 80 (2014), 1–11.
82. 82 Benlahrech, A, Harris, J, Meiser, A, Papagatsias, T, Hornig, J, Hayes, P, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 106 (2009), 19940–19945.
83. 83 Pitisuttithum, P, Rerks-Ngarm, S, Bussaratid, V, Dhitavat, J, Maekanantawat, W, Pungpak, S, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One, 6, 2011, e27837.
84. 84 Goldacre, B, Make journals report clinical trials properly. Nature, 530, 2016, 7.
85. 85 Edlefsen, PT, Rolland, M, Hertz, T, Tovanabutra, S, Gartland, AJ, deCamp, AC, et al., RV144 Sequencing Team, Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial. PLoS Comput Biol, 11, 2015, e1003973.
86. 86 McMichael, AJ, Haynes, BF, Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 13 (2012), 423–427.
87. 87 Evans, DT, Silvestri, G, Nonhuman primate models in AIDS research. Curr Opin HIV AIDS 8 (2013), 255–261.
88. 88 Hatziioannou, T, Evans, DT, Animal models for HIV/AIDS research. Nat Rev Microbiol 10 (2012), 852–867.
89. 89 Watkins, DI, Burton, DR, Kallas, EG, Moore, JP, Koff, WC, Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14 (2008), 617–621.
90. 90 McMichael, A, Picker, LJ, Moore, JP, Burton, DR, Another HIV vaccine failure: where to next?. Nat Med 19 (2013), 1576–1577.
91. 91 Kestler, H, Kodama, T, Ringler, D, Marthas, M, Pedersen, N, Lackner, A, et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 248 (1990), 1109–1112.
92. 92 Daniel, MD, Letvin, NL, King, NW, Kannagi, M, Sehgal, PK, Hunt, RD, et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228 (1985), 1201–1204.
93. 93 Harouse, JM, Gettie, A, Eshetu, T, Tan, RC, Bohm, R, Blanchard, J, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75 (2001), 1990–1995.
94. 94 Hsu, M, Harouse, JM, Gettie, A, Buckner, C, Blanchard, J, Cheng-Mayer, C, Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol 77 (2003), 989–998.
95. 95 Gautam, R, Nishimura, Y, Lee, WR, Donau, O, Buckler-White, A, Shingai, M, et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J Virol 86 (2012), 8516–8526.
96. 96 Shingai, M, Donau, OK, Schmidt, SD, Gautam, R, Plishka, RJ, Buckler-White, A, et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Nati Acad Sci USA 109 (2012), 19769–19774.
97. 97 Koff, WC, Johnson, PR, Watkins, DI, Burton, DR, Lifson, JD, Hasenkrug, KJ, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7 (2006), 19–23.
98. 98 Daniel, MD, Kirchhoff, F, Czajak, SC, Sehgal, PK, Desrosiers, RC, Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258 (1992), 1938–1941.
99. 99 Almond, N, Kent, K, Cranage, M, Rud, E, Clarke, B, Stott, EJ, Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345 (1995), 1342–1344.
100. 100 Wyand, MS, Manson, KH, Garcia-Moll, M, Montefiori, D, Desrosiers, RC, Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 70 (1996), 3724–3733.
101. 101 Norley, S, Beer, B, Binninger-Schinzel, D, Cosma, C, Kurth, R, Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus. Virology 219 (1996), 195–205.
102. 102 Connor, RI, Montefiori, DC, Binley, JM, Moore, JP, Bonhoeffer, S, Gettie, A, et al. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 72 (1998), 7501–7509.
103. 103 Johnson, RP, Lifson, JD, Czajak, SC, Cole, KS, Manson, KH, Glickman, R, et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73 (1999), 4952–4961.
104. 104 Mori, K, Yasutomi, Y, Ohgimoto, S, Nakasone, T, Takamura, S, Shioda, T, et al. Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. J Virol 75 (2001), 4023–4028.
105. 105 Manrique, J, Piatak, M, Lauer, W, Johnson, W, Mansfield, K, Lifson, J, et al. Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus. J Virol 87 (2013), 7246–7254.
106. 106 Nilsson, C, Mäkitalo, B, Thorstensson, R, Norley, S, Binninger-Schinzel, D, Cranage, M, et al. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12 (1998), 2261–2270.
107. 107 Wyand, MS, Manson, K, Montefiori, DC, Lifson, JD, Johnson, RP, Desrosiers, RC, Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 73 (1999), 8356–8363.
108. 108 Reynolds, MR, Weiler, AM, Weisgrau, KL, Piaskowski, SM, Furlott, JR, Weinfurter, JT, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 205 (2008), 2537–2550.
109. 109 Reynolds, MR, Weiler, AM, Piaskowski, SM, Kolar, HL, Hessell, AJ, Weiker, M, et al. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 84 (2010), 9190–9199.
110. 110 Berry, N, Ham, C, Mee, ET, Rose, NJ, Mattiuzzo, G, Jenkins, A, et al. Early potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques. PLoS One, 6, 2011, e23092.
111. 111 Byrareddy, SN, Ayash-Rashkovsky, M, Kramer, VG, Lee, SJ, Correll, M, Novembre, FJ, et al. Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques. PLoS One, 8, 2013, e75556.
112. 112 Piantadosi, A, Chohan, B, Chohan, V, McClelland, RS, Overbaugh, J, Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog, 3, 2007, e177.
113. 113 Jost, S, Bernard, MC, Kaiser, L, Yerly, S, Hirschel, B, Samri, A, et al. A patient with HIV-1 superinfection. N Engl J Med 347 (2002), 731–736.
114. 114 Altfeld, M, Allen, TM, Yu, XG, Johnston, MN, Agrawal, D, Korber, BT, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420 (2002), 434–439.
115. 115 Ronen, K, McCoy, CO, Matsen, FA, Boyd, DF, Emery, S, Odem-Davis, K, et al. HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog, 9, 2013, e1003593.
116. 116 Blish, CA, Dogan, OC, Jaoko, W, McClelland, RS, Mandaliya, K, Odem-Davis, K, et al. Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection. J Virol 88 (2014), 5894–5899.
117. 117 Hansen, SG, Vieville, C, Whizin, N, Coyne-Johnson, L, Siess, DC, Drummond, DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15 (2009), 293–299.
118. 118 Hansen, SG, Ford, JC, Lewis, MS, Ventura, AB, Hughes, CM, Coyne-Johnson, L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473 (2011), 523–527.
119. 119 Hansen, SG, Piatak, M Jr, Ventura, AB, Hughes, CM, Gilbride, RM, Ford, JC, et al. Immune clearance of highly pathogenic SIV infection. Nature 502 (2013), 100–104.
120. 120 Hansen, SG, Sacha, JB, Hughes, CM, Ford, JC, Burwitz, BJ, Scholz, I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science, 340, 2013, 1237874.
121. 121 Hansen, SG, Wu, HL, Burwitz, BJ, Hughes, CM, Hammond, KB, Ventura, AB, et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science 351 (2016), 714–720.
122. 122 Hansen, SG, Strelow, LI, Franchi, DC, Anders, DG, Wong, SW, Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 77 (2003), 6620–6636.
123. 123 Lilja, AE, Shenk, T, Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proceed Natl Acad Sci USA 105 (2008), 19950–19955.
124. 124 Parks, CL, Picker, LJ, King, CR, Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 8 (2013), 402–411.
125. 125 Barouch, DH, Picker, LJ, Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12 (2014), 765–771.
126. 126 Ondondo, BO, The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol, 5, 2014, 439.
127. 127 Safrit, JT, Fast, PE, Gieber, L, Kuipers, H, Dean, HJ, Koff, WC, Status of vaccine research and development of vaccines for HIV-1. Vaccine 34 (2016), 2921–2925.
128. 128 Barouch, DH, Liu, J, Li, H, Maxfield, LF, Abbink, P, Lynch, DM, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482 (2012), 89–93.
129. 129 Barouch, DH, Alter, G, Broge, T, Linde, C, Ackerman, ME, Brown, EP, et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349 (2015), 320–324.
130. 130 Baden, LR, Walsh, SR, Seaman, MS, Tucker, RP, Krause, KH, Patel, A, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis 207 (2013), 240–247.
131. 131 Barouch, DH, Liu, J, Peter, L, Abbink, P, Iampietro, MJ, Cheung, A, et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J Infect Dis 207 (2013), 248–256.
132. 132 Baden, LR, Liu, J, Li, H, Johnson, JA, Walsh, SR, Kleinjan, JA, et al. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis 211 (2015), 518–528.
133. 133 Bilello, JP, Manrique, JM, Shin, YC, Lauer, W, Li, W, Lifson, JD, et al. Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus. J Virol 85 (2011), 12708–12720.
134. 134 Shin, YC, Bischof, GF, Lauer, WA, Desrosiers, RC, Importance of codon usage for the temporal regulation of viral gene expression. Proceed Natl Acad Sci USA 112 (2015), 14030–14035.
135. 135 Sun, C, Chen, Z, Tang, X, Zhang, Y, Feng, L, Du, Y, et al. Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. J Virol 87 (2013), 5669–5677.
136. 136 Kwa, S, Lai, L, Gangadhara, S, Siddiqui, M, Pillai, VB, Labranche, C, et al. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. J Virol 88 (2014), 9579–9589.
137. 137 Lai, L, Kwa, S, Kozlowski, PA, Montefiori, DC, Ferrari, G, Johnson, WE, et al. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis 204 (2011), 164–173.
138. 138 Schell, JB, Rose, NF, Bahl, K, Diller, K, Buonocore, L, Hunter, M, et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol 85 (2011), 5764–5772.
139. 139 Weiss, RA, Clapham, PR, Weber, JN, Dalgleish, AG, Lasky, LA, Berman, PW, Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 324 (1986), 572–575.
140. 140 Richman, DD, Wrin, T, Little, SJ, Petropoulos, CJ, Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceed Natl Acad Sci USA 100 (2003), 4144–4149.
141. 141 Wei, X, Decker, JM, Wang, S, Hui, H, Kappes, JC, Wu, X, et al. Antibody neutralization and escape by HIV-1. Nature 422 (2003), 307–312.
142. 142 Laird, ME, Igarashi, T, Martin, MA, Desrosiers, RC, Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol 82 (2008), 11054–11065.
143. 143 Burns, DP, Desrosiers, RC, Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys. J Virol 65 (1991), 1843–1854.
144. 144 Burton, DR, Hangartner, L, Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol 34 (2016), 635–659.
145. 145 Sanchez-Merino, V, Fabra-Garcia, A, Gonzalez, N, Nicolas, D, Merino-Mansilla, A, Manzardo, C, et al. Detection of broadly neutralizing activity within the first months of HIV-1 infection. J Virol 90 (2016), 5231–5245.
146. 146 Doria-Rose, NA, Klein, RM, Manion, MM, O'Dell, S, Phogat, A, Chakrabarti, B, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 83 (2009), 188–199.
147. 147 Mikell, I, Sather, DN, Kalams, SA, Altfeld, M, Alter, G, Stamatatos, L, Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog, 7, 2011, e1001251.
148. 148 Gray, ES, Madiga, MC, Hermanus, T, Moore, PL, Wibmer, CK, Tumba, NL, et al., CAPRISA002 Study Team, The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85 (2011), 4828–4840.
149. 149 Klein, F, Mouquet, H, Dosenovic, P, Scheid, JF, Scharf, L, Nussenzweig, MC, Antibodies in HIV-1 vaccine development and therapy. Science 341 (2013), 1199–1204.
150. 150 Mouquet, H, Antibody B cell responses in HIV-1 infection. Trends Immunol 35 (2014), 549–561.
151. 151 McCoy, LE, Weiss, RA, Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 210 (2013), 209–223.
152. 152 Burton, DR, Desrosiers, RC, Doms, RW, Koff, WC, Kwong, PD, Moore, JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5 (2004), 233–236.
153. 153 Kepler, TB, Liao, HX, Alam, SM, Bhaskarabhatla, R, Zhang, R, Yandava, C, et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe 16 (2014), 304–313.
154. 154 Klein, F, Diskin, R, Scheid, JF, Gaebler, C, Mouquet, H, Georgiev, IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153 (2013), 126–138.
155. 155 Kwong, PD, Mascola, JR, Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37 (2012), 412–425.
156. 156 Sadanand, S, Suscovich, TJ, Alter, G, Broadly neutralizing antibodies against HIV: new insights to inform vaccine design. Annu Rev Med 67 (2016), 185–200.
157. 157 Rappuoli, R, Bottomley, MJ, D'Oro, U, Finco, O, De Gregorio, E, Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 213 (2016), 469–481.
158. 158 MacLeod, DT, Choi, NM, Briney, B, Garces, F, Ver, LS, Landais, E, et al., IAVI Protocol C Investigators & The IAVI African HIV Research Network, Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the Env high-mannose patch. Immunity 44 (2016), 1215–1226.
159. 159 Gorman, J, Soto, C, Yang, MM, Davenport, TM, Guttman, M, Bailer, RT, et al., NISC Comparative Sequencing Program, Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol 23 (2016), 81–90.
160. 160 Bonsignori, M, Zhou, T, Sheng, Z, Chen, L, Gao, F, Joyce, MG, et al., NISC Comparative Sequencing Program, Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 165 (2016), 449–463.
161. 161 Jardine, JG, Ota, T, Sok, D, Pauthner, M, Kulp, DW, Kalyuzhniy, O, et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349 (2015), 156–161.
162. 162 Sanders, RW, van Gils, MJ, Derking, R, Sok, D, Ketas, TJ, Burger, JA, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, 2015, aac4223.
163. 163 Dosenovic, P, von Boehmer, L, Escolano, A, Jardine, J, Freund, NT, Gitlin, AD, et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161 (2015), 1505–1515.
164. 164 Doria-Rose, NA, Schramm, CA, Gorman, J, Moore, PL, Bhiman, JN, DeKosky, BJ, et al., NISC Comparative Sequencing Program, Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509 (2014), 55–62.
165. 165 Georgiou, G, Ippolito, GC, Beausang, J, Busse, CE, Wardemann, H, Quake, SR, The promise and challenge of high-throughput sequencing of the antibody repertoire. Nat Biotechnol 32 (2014), 158–168.
166. 166 Liao, HX, Lynch, R, Zhou, T, Gao, F, Alam, SM, Boyd, SD, et al., NISC Comparative Sequencing Program, Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
167. 167 Corti, D, Lanzavecchia, A, Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31 (2013), 705–742.
168. 168 Haynes, BF, Kelsoe, G, Harrison, SC, Kepler, TB, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30 (2012), 423–433.
169. 169 Moore, PL, Gray, ES, Wibmer, CK, Bhiman, JN, Nonyane, M, Sheward, DJ, et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18 (2012), 1688–1692.
170. 170 Wu, X, Zhou, T, Zhu, J, Zhang, B, Georgiev, I, Wang, C, et al., NISC Comparative Sequencing Program, Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333 (2011), 1593–1602.
171. 171 Kwong, PD, Mascola, JR, Nabel, GJ, Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol 13 (2013), 693–701.
172. 172 Shcherbakov, DN, Bakulina, AY, Karpenko, LI, Ilyichev, AA, Broadly neutralizing antibodies against HIV-1 as a novel aspect of the immune response. Acta Naturae 7 (2015), 11–21.
173. 173 Burton, DR, Barbas, CF 3rd, Persson, MA, Koenig, S, Chanock, RM, Lerner, RA, et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Nati Acad Sci USA 88 (1991), 10134–10137.
174. 174 Barbas, CF 3rd, Bjorling, E, Chiodi, F, Dunlop, N, Cababa, D, Jones, TM, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Nati Acad Sci USA 89 (1992), 9339–9343.
175. 175 Muster, T, Steindl, F, Purtscher, M, Trkola, A, Klima, A, Himmler, G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67 (1993), 6642–6647.
176. 176 Buchacher, A, Predl, R, Strutzenberger, K, Steinfellner, W, Trkola, A, Purtscher, M, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10 (1994), 359–369.
177. 177 Burton, DR, Pyati, J, Koduri, R, Sharp, SJ, Thornton, GB, Parren, PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994), 1024–1027.
178. 178 Muster, T, Guinea, R, Trkola, A, Purtscher, M, Klima, A, Steindl, F, et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 68 (1994), 4031–4034.
179. 179 Conley, AJ, Kessler, JA 2nd, Boots, LJ, Tung, JS, Arnold, BA, Keller, PM, et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 91 (1994), 3348–3352.
180. 180 Trkola, A, Purtscher, M, Muster, T, Ballaun, C, Buchacher, A, Sullivan, N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 (1996), 1100–1108.
181. 181 Zwick, MB, Labrijn, AF, Wang, M, Spenlehauer, C, Saphire, EO, Binley, JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75 (2001), 10892–10905.
182. 182 Parren, PW, Gauduin, MC, Koup, RA, Poignard, P, Fisicaro, P, Burton, DR, et al. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett 57 (1997), 105–112.
183. 183 Walker, LM, Phogat, SK, Chan-Hui, PY, Wagner, D, Phung, P, Goss, JL, et al., Protocol G Principal Investigators, Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009), 285–289.
184. 184 Wu, X, Yang, ZY, Li, Y, Hogerkorp, CM, Schief, WR, Seaman, MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 (2010), 856–861.
185. 185 Scheid, JF, Mouquet, H, Ueberheide, B, Diskin, R, Klein, F, Oliveira, TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333 (2011), 1633–1637.
186. 186 Klein, F, Gaebler, C, Mouquet, H, Sather, DN, Lehmann, C, Scheid, JF, et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 209 (2012), 1469–1479.
187. 187 Walker, LM, Huber, M, Doores, KJ, Falkowska, E, Pejchal, R, Julien, JP, et al., Protocol G Principal Investigators, Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477 (2011), 466–470.
188. 188 Pejchal, R, Doores, KJ, Walker, LM, Khayat, R, Huang, PS, Wang, SK, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334 (2011), 1097–1103.
189. 189 Mouquet, H, Scharf, L, Euler, Z, Liu, Y, Eden, C, Scheid, JF, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA 109 (2012), E3268–3277.
190. 190 Huang, J, Ofek, G, Laub, L, Louder, MK, Doria-Rose, NA, Longo, NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491 (2012), 406–412.
191. 191 Kwon, YD, Georgiev, IS, Ofek, G, Zhang, B, Asokan, M, Bailer, RT, et al. Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. J Virol 90 (2016), 5899–5914.
192. 192 Huang, J, Kang, BH, Pancera, M, Lee, JH, Tong, T, Feng, Y, et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515 (2014), 138–142.
193. 193 Sok, D, van Gils, MJ, Pauthner, M, Julien, JP, Saye-Francisco, KL, Hsueh, J, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Nati Acad Sci USA 111 (2014), 17624–17629.
194. 194 Kong, R, Xu, K, Zhou, T, Acharya, P, Lemmin, T, Liu, K, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352 (2016), 828–833.
195. 195 Shibata, R, Igarashi, T, Haigwood, N, Buckler-White, A, Ogert, R, Ross, W, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5 (1999), 204–210.
196. 196 Mascola, JR, Lewis, MG, Stiegler, G, Harris, D, VanCott, TC, Hayes, D, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73 (1999), 4009–4018.
197. 197 Mascola, JR, Stiegler, G, VanCott, TC, Katinger, H, Carpenter, CB, Hanson, CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6 (2000), 207–210.
198. 198 Baba, TW, Liska, V, Hofmann-Lehmann, R, Vlasak, J, Xu, W, Ayehunie, S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6 (2000), 200–206.
199. 199 Parren, PW, Marx, PA, Hessell, AJ, Luckay, A, Harouse, J, Cheng-Mayer, C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75 (2001), 8340–8347.
200. 200 Hessell, AJ, Poignard, P, Hunter, M, Hangartner, L, Tehrani, DM, Bleeker, WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 15 (2009), 951–954.
201. 201 Hessell, AJ, Rakasz, EG, Poignard, P, Hangartner, L, Landucci, G, Forthal, DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog, 5, 2009, e1000433.
202. 202 Hessell, AJ, Rakasz, EG, Tehrani, DM, Huber, M, Weisgrau, KL, Landucci, G, et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84 (2010), 1302–1313.
203. 203 Burton, DR, Hessell, AJ, Keele, BF, Klasse, PJ, Ketas, TA, Moldt, B, et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 108 (2011), 11181–11186.
204. 204 Deruaz, M, Moldt, B, Le, KM, Power, KA, Vrbanac, VD, Tanno, S, et al. Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: a model for studying the efficacy of neutralizing antibodies in vivo. J Infect Dis 214 (2016), 612–616.
205. 205 Shingai, M, Donau, OK, Plishka, RJ, Buckler-White, A, Mascola, JR, Nabel, GJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211 (2014), 2061–2074.
206. 206 Moldt, B, Rakasz, EG, Schultz, N, Chan-Hui, PY, Swiderek, K, Weisgrau, KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA 109 (2012), 18921–18925.
207. 207 Ko, SY, Pegu, A, Rudicell, RS, Yang, ZY, Joyce, MG, Chen, X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514 (2014), 642–645.
208. 208 Saunders, KO, Pegu, A, Georgiev, IS, Zeng, M, Joyce, MG, Yang, ZY, et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against Simian/human immunodeficiency virus infection. J Virol 89 (2015), 5895–5903.
209. 209 Gautam, R, Nishimura, Y, Pegu, A, Nason, MC, Klein, F, Gazumyan, A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533 (2016), 105–109.
210. 210 Kong, R, Louder, MK, Wagh, K, Bailer, RT, deCamp, A, Greene, K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol 89 (2015), 2659–2671.
211. 211 Wagh, K, Bhattacharya, T, Williamson, C, Robles, A, Bayne, M, Garrity, J, et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. PLoS Pathog, 12, 2016, e1005520.
212. 212 Deeks, SG, HIV: shock and kill. Nature 487 (2012), 439–440.
213. 213 Hessell, AJ, Hangartner, L, Hunter, M, Havenith, CE, Beurskens, FJ, Bakker, JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
214. 214 Bournazos, S, Klein, F, Pietzsch, J, Seaman, MS, Nussenzweig, MC, Ravetch, JV, Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
215. 215 von Bredow, B, Arias, JF, Heyer, LN, Moldt, B, Le, K, Robinson, JE, et al. Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies. J Virol 90 (2016), 6127–6139.
216. 216 Lewis, GK, Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 142 (2014), 46–57.
217. 217 Bournazos, S, DiLillo, DJ, Ravetch, JV, The role of Fc-FcγR interactions in IgG-mediated microbial neutralization. J Exp Med 212 (2015), 1361–1369.
218. 218 Armbruster, C, Stiegler, GM, Vcelar, BA, Jäger, W, Michael, NL, Vetter, N, et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16 (2002), 227–233.
219. 219 Armbruster, C, Stiegler, GM, Vcelar, BA, Jäger, W, Köller, U, Jilch, R, et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 54 (2004), 915–920.
220. 220 Stephenson, KE, Barouch, DH, Broadly neutralizing antibodies for HIV eradication. Curr HIV/AIDS Rep 13 (2016), 31–37.
221. 221 Stiegler, G, Armbruster, C, Vcelar, B, Stoiber, H, Kunert, R, Michael, NL, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16 (2002), 2019–2025.
222. 222 Trkola, A, Kuster, H, Rusert, P, Joos, B, Fischer, M, Leemann, C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11 (2005), 615–622.
223. 223 Mehandru, S, Vcelar, B, Wrin, T, Stiegler, G, Joos, B, Mohri, H, et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol 81 (2007), 11016–11031.
224. 224 Ledgerwood, JE, Coates, EE, Yamshchikov, G, Saunders, JG, Holman, L, Enama, ME, et al., VRC 602 Study Team, Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 182 (2015), 289–301.
225. 225 Lu, CL, Murakowski, DK, Bournazos, S, Schoofs, T, Sarkar, D, Halper-Stromberg, A, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352 (2016), 1001–1004.
226. 226 Schoofs, T, Klein, F, Braunschweig, M, Kreider, EF, Feldmann, A, Nogueira, L, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
227. 227 Scheid, JF, Horwitz, JA, Bar-On, Y, Kreider, EF, Lu, CL, Lorenzi, JC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535 (2016), 556–560.
228. 228 Gorlani, A, Forthal, DN, Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res 11 (2013), 421–426.
229. 229 Mascola, JR, Mathieson, BJ, Zack, PM, Walker, MC, Halstead, SB, Burke, DS, Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 9 (1993), 1175–1184.
230. 230 Robinson, WE Jr, Montefiori, DC, Mitchell, WM, Prince, AM, Alter, HJ, Dreesman, GR, et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Nati Acad Sci USA 86 (1989), 4710–4714.
231. 231 Huang, Y, Yu, J, Lanzi, A, Yao, X, Andrews, CD, Tsai, L, et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell 165 (2016), 1621–1631.
232. 232 Bournazos, S, Gazumyan, A, Seaman, MS, Nussenzweig, MC, Ravetch, JV, Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165 (2016), 1609–1620.
233. 233 Hua, CK, Ackerman, ME, Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev 103 (2016), 157–173.
234. 234 Sips, M, Krykbaeva, M, Diefenbach, TJ, Ghebremichael, M, Bowman, BA, Dugast, AS, et al. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol 9 (2016), 1584–1595.
235. 235 Sung, JA, Pickeral, J, Liu, L, Stanfield-Oakley, SA, Lam, CY, Garrido, C, et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest 125 (2015), 4077–4090.
236. 236 Sloan, DD, Lam, CY, Irrinki, A, Liu, L, Tsai, A, Pace, CS, et al. Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells. PLoS Pathog, 11, 2015, e1005233.
237. 237 Boesch, AW, Alter, G, Ackerman, ME, Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr Opin HIV AIDS 10 (2015), 160–169.
238. 238 Asokan, M, Rudicell, RS, Louder, M, McKee, K, O'Dell, S, Stewart-Jones, G, et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. J Virol 89 (2015), 12501–12512.
239. 239 Grevys, A, Bern, M, Foss, S, Bratlie, DB, Moen, A, Gunnarsen, KS, et al. Fc engineering of human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. J Immunol 194 (2015), 5497–5508.
240. 240 Bournazos, S, Chow, SK, Abboud, N, Casadevall, A, Ravetch, JV, Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J Clin Invest 124 (2014), 725–729.
241. 241 Romain, G, Senyukov, V, Rey-Villamizar, N, Merouane, A, Kelton, W, Liadi, I, et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood 124 (2014), 3241–3249.
242. 242 Mouquet, H, Warncke, M, Scheid, JF, Seaman, MS, Nussenzweig, MC, Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci USA 109 (2012), 875–880.
243. 243 Ackerman, ME, Dugast, AS, Alter, G, Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med 63 (2012), 113–130.
244. 244 Schaefer, W, Regula, JT, Bahner, M, Schanzer, J, Croasdale, R, Durr, H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108 (2011), 11187–11192.
245. 245 Moore, GL, Chen, H, Karki, S, Lazar, GA, Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2 (2010), 181–189.
246. 246 Strohl, WR, Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20 (2009), 685–691.
247. 247 Lazar, GA, Dang, W, Karki, S, Vafa, O, Peng, JS, Hyun, L, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103 (2006), 4005–4010.
248. 248 Kotterman, MA, Chalberg, TW, Schaffer, DV, Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17 (2015), 63–89.
249. 249 Samulski, RJ, Muzyczka, N, AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1 (2014), 427–451.
250. 250 Kotterman, MA, Schaffer, DV, Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15 (2014), 445–451.
251. 251 Wang, D, Zhong, L, Nahid, MA, Gao, G, The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11 (2014), 345–364.
252. 252 Balakrishnan, B, Jayandharan, GR, Basic biology of adeno-associated virus (AAV) vectors used in gene therapy. Curr Gene Ther 14 (2014), 86–100.
253. 253 Mingozzi, F, High, KA, Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12 (2011), 341–355.
254. 254 Daya, S, Berns, KI, Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21 (2008), 583–593.
255. 255 Gil-Farina, I, Fronza, R, Kaeppel, C, Lopez-Franco, E, Ferreira, V, D'Avola, D, et al. Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther 24 (2016), 1100–1105.
256. 256 Berns, KI, Byrne, BJ, Flotte, TR, Gao, G, Hauswirth, WW, Herzog, RW, et al. Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther 26 (2015), 779–781.
257. 257 Kaeppel, C, Beattie, SG, Fronza, R, van Logtenstein, R, Salmon, F, Schmidt, S, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 19 (2013), 889–891.
258. 258 Ye, GJ, Budzynski, E, Sonnentag, P, Nork, TM, Miller, PE, Sharma, AK, et al. Safety and biodistribution evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a recombinant AAV vector for treatment of achromatopsia. Hum Gene Ther Clin Dev 27 (2016), 37–48.
259. 259 Mancuso, K, Hauswirth, WW, Li, Q, Connor, TB, Kuchenbecker, JA, Mauck, MC, et al. Gene therapy for red-green colour blindness in adult primates. Nature 461 (2009), 784–787.
260. 260 Nathwani, AC, Gray, JT, McIntosh, J, Ng, CY, Zhou, J, Spence, Y, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109 (2007), 1414–1421.
261. 261 Rivera, VM, Gao, GP, Grant, RL, Schnell, MA, Zoltick, PW, Rozamus, LW, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105 (2005), 1424–1430.
262. 262 Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003), 2963–2972.
263. 263 Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12 (2006), 342–347.
264. 264 Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
265. 265 Nathwani, AC, Reiss, UM, Tuddenham, EG, Rosales, C, Chowdary, P, McIntosh, J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371 (2014), 1994–2004.
266. 266 Stroes, ES, Nierman, MC, Meulenberg, JJ, Franssen, R, Twisk, J, Henny, CP, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28 (2008), 2303–2304.
267. 267 Gaudet, D, Méthot, J, Déry, S, Brisson, D, Essiembre, C, Tremblay, G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 20 (2013), 361–369.
268. 268 Brantly, ML, Chulay, JD, Wang, L, Mueller, C, Humphries, M, Spencer, LT, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natil Acad Sci USA 106 (2009), 16363–16368.
269. 269 Flotte, TR, Trapnell, BC, Humphries, M, Carey, B, Calcedo, R, Rouhani, F, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther 22 (2011), 1239–1247.
270. 270 MacLaren, RE, Groppe, M, Barnard, AR, Cottriall, CL, Tolmachova, T, Seymour, L, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase ½ clinical trial. Lancet 383 (2014), 1129–1137.
271. 271 Bowles, DE, McPhee, SW, Li, C, Gray, SJ, Samulski, JJ, Camp, AS, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20 (2012), 443–455.
272. 272 Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
273. 273 Jacobson, SG, Cideciyan, AV, Ratnakaram, R, Heon, E, Schwartz, SB, Roman, AJ, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130 (2012), 9–24.
274. 274 LeWitt, PA, Rezai, AR, Leehey, MA, Ojemann, SG, Flaherty, AW, Eskandar, EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10 (2011), 309–319.
275. 275 Bennett, J, Ashtari, M, Wellman, J, Marshall, KA, Cyckowski, LL, Chung, DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med, 4, 2012, 120ra15.
276. 276 Ylä-Herttuala, S, Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 20 (2012), 1831–1832.
277. 277 Bryant, LM, Christopher, DM, Giles, AR, Hinderer, C, Rodriguez, JL, Smith, JB, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 24 (2013), 55–64.
278. 278 Scott, LJ, Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. Drugs 75 (2015), 175–182.
279. 279 Kastelein, JJ, Ross, CJ, Hayden, MR, From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Hum Gene Ther 24 (2013), 472–478.
280. 280 Hermonat, PL, Muzyczka, N, Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 81 (1984), 6466–6470.
281. 281 McLaughlin, SK, Collis, P, Hermonat, PL, Muzyczka, N, Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 62 (1988), 1963–1973.
282. 282 Samulski, RJ, Chang, LS, Shenk, T, Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 63 (1989), 3822–3828.
283. 283 Gonçalves, MA, Adeno-associated virus: from defective virus to effective vector. Virol J, 2, 2005, 43.
284. 284 Le Bec, C, Douar, AM, Gene therapy progress and prospects–vectorology: design and production of expression cassettes in AAV vectors. Gene Ther 13 (2006), 805–813.
285. 285 Schnepp, BC, Clark, KR, Klemanski, DL, Pacak, CA, Johnson, PR, Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 77 (2003), 3495–3504.
286. 286 Schnepp, BC, Chulay, JD, Ye, GJ, Flotte, TR, Trapnell, BC, Johnson, PR, Recombinant adeno-associated virus vector genomes take the form of long-lived, transcriptionally competent episomes in human muscle. Hum Gene Ther 27 (2016), 32–42.
287. 287 Flotte, TR, Mueller, C, Gernoux, G, Gruntman, A, Chulay, JD, Knop, DR, et al. Sustained Expression with Partial Correction of Neutrophil Defects 5 Years After Intramuscular rAAV1 Gene Therapy for Alpha-1 Antitrypsin Deficiency. http://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1385&context=cts_retreat, 2016.
288. 288 Saunders, KO, Wang, L, Joyce, MG, Yang, ZY, Balazs, AB, Cheng, C, et al. Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects nonhuman primates from mucosal Simian-human immunodeficiency virus infection. J Virol 89 (2015), 8334–8345.
289. 289 Mellins, ED, Kay, MA, Viral vectors take on HIV infection. N Engl J Med 373 (2015), 770–772.
290. 290 Muzyczka, N, Berns, KI, AAV's Golden Jubilee. Mol Ther 23 (2015), 807–808.
291. 291 Balazs, AB, Ouyang, Y, Hong, CM, Chen, J, Nguyen, SM, Rao, DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20 (2014), 296–300.
292. 292 McCarty, DM, Self-complementary AAV vectors; advances and applications. Mol Ther 16 (2008), 1648–1656.
293. 293 McCarty, DM, Monahan, PE, Samulski, RJ, Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8 (2001), 1248–1254.
294. 294 Wu, Z, Yang, H, Colosi, P, Effect of genome size on AAV vector packaging. Mol Ther 18 (2010), 80–86.
295. 295 Wu, J, Zhao, W, Zhong, L, Han, Z, Li, B, Ma, W, et al. Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther 18 (2007), 171–182.
296. 296 Fuchs, SP, Martinez-Navio, JM, Gao, G, Desrosiers, RC, Recombinant AAV vectors for enhanced expression of authentic IgG. PLoS One, 11, 2016, e0158009.
297. 297 Fang, J, Qian, JJ, Yi, S, Harding, TC, Tu, GH, VanRoey, M, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23 (2005), 584–590.
298. 298 Fang, J, Yi, S, Simmons, A, Tu, GH, Nguyen, M, Harding, TC, et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 15 (2007), 1153–1159.
299. 299 Choe, H, Li, W, Wright, PL, Vasilieva, N, Venturi, M, Huang, CC, et al. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114 (2003), 161–170.
300. 300 Dorfman, T, Moore, MJ, Guth, AC, Choe, H, Farzan, M, A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 281 (2006), 28529–28535.
301. 301 Chiang, JJ, Gardner, MR, Quinlan, BD, Dorfman, T, Choe, H, Farzan, M, Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants. J Virol 86 (2012), 12417–12421.
302. 302 Gardner, MR, Fellinger, CH, Prasad, NR, Zhou, AS, Kondur, HR, Joshi, VR, et al. CD4-induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. J Virol 90 (2016), 7822–7832.
303. 303 Mingozzi, F, Büning, H, Adeno-associated viral vectors at the frontier between tolerance and immunity. Front Immunol, 6, 2015, 120.
304. 304 Mingozzi, F, High, KA, Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
305. 305 Hareendran, S, Balakrishnan, B, Sen, D, Kumar, S, Srivastava, A, Jayandharan, GR, Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol 23 (2013), 399–413.
306. 306 Ferreira, V, Petry, H, Salmon, F, Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol, 5, 2014, 82.
307. 307 Rogers, GL, Martino, AT, Aslanidi, GV, Jayandharan, GR, Srivastava, A, Herzog, RW, Innate immune responses to AAV vectors. Front Microbiol, 2, 2011, 194.
308. 308 Basner-Tschakarjan, E, Mingozzi, F, Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions. Front Immunol, 5, 2014, 350.
309. 309 Calcedo, R, Wilson, JM, Humoral immune response to AAV. Front Immunol, 4, 2013, 341.
310. 310 Veron, P, Leborgne, C, Monteilhet, V, Boutin, S, Martin, S, Moullier, P, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol 188 (2012), 6418–6424.
311. 311 Gao, G, Vandenberghe, LH, Wilson, JM, New recombinant serotypes of AAV vectors. Curr Gene Ther 5 (2005), 285–297.
312. 312 Gao, G, Vandenberghe, LH, Alvira, MR, Lu, Y, Calcedo, R, Zhou, X, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78 (2004), 6381–6388.
313. 313 Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J, Wilson, JM, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Nati Acad Sci USA 99 (2002), 11854–11859.
314. 314 Hösel, M, Broxtermann, M, Janicki, H, Esser, K, Arzberger, S, Hartmann, P, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 55 (2012), 287–297.
315. 315 Zhu, J, Huang, X, Yang, Y, The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 119 (2009), 2388–2398.
316. 316 Martino, AT, Suzuki, M, Markusic, DM, Zolotukhin, I, Ryals, RC, Moghimi, B, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117 (2011), 6459–6468.
317. 317 Faust, SM, Bell, P, Cutler, BJ, Ashley, SN, Zhu, Y, Rabinowitz, JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 123 (2013), 2994–3001.
318. 318 Sudres, M, Ciré, S, Vasseur, V, Brault, L, Da Rocha, S, Boisgérault, F, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther 20 (2012), 1571–1581.
319. 319 Calcedo, R, Vandenberghe, LH, Gao, G, Lin, J, Wilson, JM, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199 (2009), 381–390.
320. 320 Boutin, S, Monteilhet, V, Veron, P, Leborgne, C, Benveniste, O, Montus, MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21 (2010), 704–712.
321. 321 Calcedo, R, Wilson, JM, AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees. Hum Gene Ther Clin Dev 27 (2016), 79–82.
322. 322 Scallan, CD, Jiang, H, Liu, T, Patarroyo-White, S, Sommer, JM, Zhou, S, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107 (2006), 1810–1817.
323. 323 Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108 (2006), 3321–3328.
324. 324 Murphy, SL, Li, H, Zhou, S, Schlachterman, A, High, KA, High, K, Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. Mol Ther 16 (2008), 138–145.
325. 325 Fisher, KJ, Jooss, K, Alston, J, Yang, Y, Haecker, SE, High, K, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3 (1997), 306–312.
326. 326 Rivière, C, Danos, O, Douar, AM, Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther 13 (2006), 1300–1308.
327. 327 Petry, H, Brooks, A, Orme, A, Wang, P, Liu, P, Xie, J, et al. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. Gene Ther 15 (2008), 54–60.
328. 328 Manning, WC, Zhou, S, Bland, MP, Escobedo, JA, Dwarki, V, Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 9 (1998), 477–485.
329. 329 Halbert, CL, Standaert, TA, Wilson, CB, Miller, AD, Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 72 (1998), 9795–9805.
330. 330 Chirmule, N, Xiao, W, Truneh, A, Schnell, MA, Hughes, JV, Zoltick, P, et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 74 (2000), 2420–2425.
331. 331 Pien, GC, Basner-Tschakarjan, E, Hui, DJ, Mentlik, AN, Finn, JD, Hasbrouck, NC, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 119 (2009), 1688–1695.
332. 332 Rogers, GL, Martino, AT, Zolotukhin, I, Ertl, HC, Herzog, RW, Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med, 12, 2014, 25.
333. 333 Cao, O, Hoffman, BE, Moghimi, B, Nayak, S, Cooper, M, Zhou, S, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17 (2009), 1733–1742.
334. 334 Fields, PA, Arruda, VR, Armstrong, E, Chu, K, Mingozzi, F, Hagstrom, JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther 4 (2001), 201–210.
335. 335 Herzog, RW, Hagstrom, JN, Kung, SH, Tai, SJ, Wilson, JM, Fisher, KJ, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94 (1997), 5804–5809.
336. 336 Herzog, RW, Yang, EY, Couto, LB, Hagstrom, JN, Elwell, D, Fields, PA, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5 (1999), 56–63.
337. 337 Mendell, JR, Campbell, K, Rodino-Klapac, L, Sahenk, Z, Shilling, C, Lewis, S, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363 (2010), 1429–1437.
338. 338 Li, C, Goudy, K, Hirsch, M, Asokan, A, Fan, Y, Alexander, J, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci USA 106 (2009), 10770–10774.
339. 339 Markusic, DM, Hoffman, BE, Perrin, GQ, Nayak, S, Wang, X, LoDuca, PA, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med 5 (2013), 1698–1709.
340. 340 Mays, LE, Vandenberghe, LH, Xiao, R, Bell, P, Nam, HJ, Agbandje-McKenna, M, et al. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J Immunol 182 (2009), 6051–6060.
341. 341 Mays, LE, Wilson, JM, The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 19 (2011), 16–27.
342. 342 Lu, Y, Song, S, Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci USA 106 (2009), 17158–17162.
343. 343 Sen, D, Gadkari, RA, Sudha, G, Gabriel, N, Kumar, YS, Selot, R, et al. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum Gene Ther Methods 24 (2013), 104–116.
344. 344 Wang, L, Louboutin, JP, Bell, P, Greig, JA, Li, Y, Wu, D, et al. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb Haemost 9 (2011), 2009–2019.
345. 345 Wu, T, Töpfer, K, Lin, SW, Li, H, Bian, A, Zhou, XY, et al. Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther 20 (2012), 572–579.
346. 346 Greig, JA, Peng, H, Ohlstein, J, Medina-Jaszek, CA, Ahonkhai, O, Mentzinger, A, et al. Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One, 9, 2014, e112268.
347. 347 Li, C, Diprimio, N, Bowles, DE, Hirsch, ML, Monahan, PE, Asokan, A, et al. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol 86 (2012), 7752–7759.
348. 348 Toromanoff, A, Adjali, O, Larcher, T, Hill, M, Guigand, L, Chenuaud, P, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther 18 (2010), 151–160.
349. 349 Xin, KQ, Mizukami, H, Urabe, M, Toda, Y, Shinoda, K, Yoshida, A, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 80 (2006), 11899–11910.
350. 350 Veron, P, Allo, V, Rivière, C, Bernard, J, Douar, AM, Masurier, C, Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol 81 (2007), 5385–5394.
351. 351 Schroeder, HW Jr, Cavacini, L, Structure and function of immunoglobulins. J Allergy Clin Immunol 125:2 Suppl 2 (2010), S41–S52.
352. 352 Mix, E, Goertsches, R, Zett, UK, Immunoglobulins–basic considerations. J Neurol 253 Suppl 5 (2006), V9–17.
353. 353 Melchers, F, Checkpoints that control B cell development. J Clin Invest 125 (2015), 2203–2210.
354. 354 Wardemann, H, Yurasov, S, Schaefer, A, Young, JW, Meffre, E, Nussenzweig, MC, Predominant autoantibody production by early human B cell precursors. Science 301 (2003), 1374–1377.
355. 355 Wardemann, H, Nussenzweig, MC, B-cell self-tolerance in humans. Adv Immunol 95 (2007), 83–110.
356. 356 Mouquet, H, Nussenzweig, MC, Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci 69 (2012), 1435–1445.
357. 357 Sok, D, Laserson, U, Laserson, J, Liu, Y, Vigneault, F, Julien, JP, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog, 9, 2013, e1003754.
358. 358 Mouquet, H, Scheid, JF, Zoller, MJ, Krogsgaard, M, Ott, RG, Shukair, S, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467 (2010), 591–595.
359. 359 Martinez-Navio, JM, Fuchs, SP, Pedreño-López, S, Rakasz, EG, Gao, G, Desrosiers, RC, Host anti-antibody responses following adeno-associated virus-mediated delivery of antibodies against HIV and SIV in Rhesus monkeys. Mol Ther 24 (2016), 76–86.
360. 360 Breden, F, Lepik, C, Longo, NS, Montero, M, Lipsky, PE, Scott, JK, Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One, 6, 2011, e16857.
361. 361 Harding, FA, Stickler, MM, Razo, J, DuBridge, RB, The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2 (2010), 256–265.
362. 362 Krishna, M, Nadler, SG, Immunogenicity to biotherapeutics - the role of anti-drug immune complexes. Front Immunol, 7, 2016, 21.
363. 363 Scott, DW, De Groot, AS, Can we prevent immunogenicity of human protein drugs?. Ann Rheum Dis 69 Suppl 1 (2010), i72–i76.
364. 364 van Beers, MM, Bardor, M, Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 7 (2012), 1473–1484.
365. 365 Baker, MP, Reynolds, HM, Lumicisi, B, Bryson, CJ, Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1 (2010), 314–322.
366. 366 Bartelds, GM, Wolbink, GJ, Stapel, S, Aarden, L, Lems, WF, Dijkmans, BA, et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 65 (2006), 1249–1250.
367. 367 Wang, W, Wang, EQ, Balthasar, JP, Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84 (2008), 548–558.
368. 368 Radstake, TR, Svenson, M, Eijsbouts, AM, van den Hoogen, FH, Enevold, C, van Riel, PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68 (2009), 1739–1745.
369. 369 van Meer, PJ, Kooijman, M, Brinks, V, Gispen-de Wied, CC, Silva-Lima, B, Moors, EH, et al. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs 5 (2013), 810–816.
370. 370 Hwang, WY, Foote, J, Immunogenicity of engineered antibodies. Methods 36 (2005), 3–10.
371. 371 Thullier, P, Chahboun, S, Pelat, T, A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2 (2010), 528–538.
372. 372 West, AP Jr, Galimidi, RP, Gnanapragasam, PN, Bjorkman, PJ, Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol 86 (2012), 195–202.
373. 373 Rudicell, RS, Kwon, YD, Ko, SY, Pegu, A, Louder, MK, Georgiev, IS, et al., NISC Comparative Sequencing Program, Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88 (2014), 12669–12682.
374. 374 Corti, M, Elder, M, Falk, D, Lawson, L, Smith, B, Nayak, S, et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev, 1, 2014, 14033 doi:14010.11038/mtm.12014.14033.
375. 375 Wagner, CL, Schantz, A, Barnathan, E, Olson, A, Mascelli, MA, Ford, J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 112 (2003), 37–53.
376. 376 Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 105 (2008), 7827–7832.
377. 377 Qiao, C, Zhang, W, Yuan, Z, Shin, JH, Li, J, Jayandharan, GR, et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 21 (2010), 1343–1348.
378. 378 Vercauteren, K, Hoffman, BE, Zolotukhin, I, Keeler, GD, Xiao, JW, Basner-Tschakarjan, E, et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther 24 (2016), 1042–1049.
379. 379 Majowicz, A, Maczuga, P, Kwikkers, KL, van der Marel, S, van Logtenstein, R, Petry, H, et al. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. J Gene Med 15 (2013), 219–232.
380. 380 Boisgerault, F, Gross, DA, Ferrand, M, Poupiot, J, Darocha, S, Richard, I, et al. Prolonged gene expression in muscle is achieved without active immune tolerance using microrRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther 24 (2013), 393–405.
381. 381 Wang, X, Terhorst, C, Herzog, RW, In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol 301 (2016), 18–29.
382. 382 Sharland, A, Logan, GJ, Bishop, A, Alexander, IE, Liver-directed gene expression using recombinant AAV 2/8 vectors–a tolerogenic strategy for gene delivery?. Discov Med 9 (2010), 519–527.
383. 383 Sack, BK, Herzog, RW, Terhorst, C, Markusic, DM, Development of gene transfer for induction of antigen-specific tolerance. Mol Ther Methods Clin Dev, 1, 2014, 14013.
384. 384 Mueller, C, Chulay, JD, Trapnell, BC, Humphries, M, Carey, B, Sandhaus, RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 123 (2013), 5310–5318.
385. 385 Mays, LE, Wang, L, Lin, J, Bell, P, Crawford, A, Wherry, EJ, et al. AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 22 (2014), 28–41.
386. 386 LoDuca, PA, Hoffman, BE, Herzog, RW, Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther 9 (2009), 104–114.
387. 387 Büning, H, Schmidt, M, Adeno-associated vector toxicity-to be or not to be?. Mol Ther 23 (2015), 1673–1675.